L'évaluation conjointe du contenu en ADN et de la fraction de cellules en phase S est un paramètre pronostique indépendant dans les cancers du sein de stades I et II

[1]  S. Delaloge,et al.  Bases génétiques de la radiosensibilité des cancers du sein , 2005 .

[2]  T. Delozier,et al.  Proliferative activity in primary breast carcinomas is a salient prognostic factor , 2004, Cancer.

[3]  A. Ramaioli,et al.  Prognostic value of S-phase fraction in 920 breast cancer patients: focus on T1N0 status. , 2003, The International journal of biological markers.

[4]  M. L.,et al.  Standards, Options et Recommandations 2001 pour la radiothérapie des patientes atteintes d'un cancer du sein infiltrant non métastatique, mise à jour , 2002 .

[5]  M. Bolla,et al.  S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J F Simpson,et al.  Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Michels,et al.  Variation of flow cytometric DNA measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram interpretation. , 2000, Cytometry.

[8]  M. Bolla,et al.  [Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer: multicentric retrospective study II. DNA-ploidy and S-phase fraction]. , 1999, Bulletin du cancer.

[9]  M. Fernö,et al.  Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.

[10]  A. Thor,et al.  Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Thomas J. Smith,et al.  1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. de Toma,et al.  Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  N. Harbeck,et al.  Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. , 1997, British Journal of Cancer.

[14]  B. Asselain,et al.  S-phase fractions of breast cancer predict overall and post-relapse survival. , 1997, European journal of cancer.

[15]  M. Daidone,et al.  Cell proliferation in 3,800 node‐negative breast cancers: Concistency over time of biological and clinical information provided by 3H‐Thymidine labelling index , 1997, International journal of cancer.

[16]  D. Berry,et al.  Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. , 1995, Cytometry.

[17]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. , 1995, Journal of the National Cancer Institute.

[18]  O. Chinot,et al.  Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer , 1995, International journal of cancer.

[19]  C. E. Gillett,et al.  The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. , 1995, British Journal of Cancer.

[20]  A. Andersson,et al.  S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. , 1994, British Journal of Cancer.

[21]  F. Spyratos,et al.  Multiparametric prognostic evaluation of biological factors in primary breast cancer. , 1992, Journal of the National Cancer Institute.

[22]  C. Osborne,et al.  Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Gnant,et al.  DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study. , 1992, European journal of cancer.

[24]  M. Tubiana-Hulin,et al.  Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short‐term follow‐up , 1992, Cancer.

[25]  B. Dutrillaux,et al.  Breast cancer genetic evolution: I. Data from cytogenetics and DNA content , 1991, Breast Cancer Research and Treatment.

[26]  Å. Borg,et al.  Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas , 1991, Breast Cancer Research and Treatment.

[27]  R. Camplejohn,et al.  Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Camplejohn,et al.  DNA index, S-phase fraction, histological grade and prognosis in breast cancer. , 1990, British Journal of Cancer.

[29]  T Koivula,et al.  Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S‐phase fraction: A proposed classification of DNA histograms in breast cancer , 1988, Cancer.

[30]  A. Foltz,et al.  Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma , 1988, Cancer.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  D. Amadori,et al.  Prognostic and predictive value of thymidine labelling index in breast cancer , 2004, Breast Cancer Research and Treatment.

[33]  J. Bryant,et al.  S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer , 2004, Breast Cancer Research and Treatment.

[34]  G. Clark,et al.  S-phase fraction and breast cancer — a decade of experience , 1998 .

[35]  Brian H. Mayall,et al.  Guidelines for implementation of clinical DNA cytometry , 1993 .

[36]  D. Cox.  Regression Models and Life-Tables , 1972 .